Logo
x

Search

Subscribe Now

bayer

Bayer Reports the Regulatory Submission of Nubeqa (Darolutamide) to the EMA for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Bayer Reports the Regulatory Submission of Nubeqa (Darolutamide) to the EMA for Treating Metastatic Hormone-Sensitive Prostate Can...

  • October 14, 2024
Bayer Collaborates with MOMA Therapeutics for the Development of a Small Molecule Oncology Program

Bayer Collaborates with MOMA Therapeutics for the Development of a Small Molecule Oncology Program

  • October 9, 2024
Bayer Reports Regulatory Submission of Nubeqa to the US FDA for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Bayer Reports Regulatory Submission of Nubeqa to the US FDA for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

  • September 26, 2024
Bayer Reports the P-III (OASIS 3) Trial Data of Elinzanetant to Treat Vasomotor Symptoms in Postmenopausal Women

Bayer Reports the P-III (OASIS 3) Trial Data of Elinzanetant to Treat Vasomotor Symptoms in Postmenopausal Women

  • September 11, 2024
Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024

Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024

  • September 10, 2024
Bayer Reports the Initiation of P-III (SOHO-02) Study of BAY 2927088 to Treat Non-Small Cell Lung Cancer (NSCLC)

Bayer Reports the Initiation of P-III (SOHO-02) Study of BAY 2927088 to Treat Non-Small Cell Lung Cancer (NSCLC)

  • August 30, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.